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INTRODUCTION
Growth factors and growth factor receptors, particularly with tyrosine kinase activity, enhance the flow of signal transmission that plays a role in the growth control and regulation of various genes related to growth and proliferation. The ErbB gene family consists of four homologous gene families: ErbB-1 (EGFR, HER1), ErbB-2 (HER2/Neu, cerbB-2), ErbB-3 (HER3) and ErbB-4 (HER4). Overexpression of the ErbB receptor has both prognostic and therapeutic significance. Since good clinical outcomes have been achieved with humanized antibody (trastuzumab) developed against ErbB-2 in breast cancer, the investigation of HER2/Neu expression and use of HER2/Neu antibody in the treatment of other solid tumors has become a current issue (1, 2) .
ErbB-2 overexpression in gastric cancer was first demonstrated by immunohistochemical (IHC) staining in 1986 (3) . Subsequently, a number of studies have been conducted on ErbB-2 gene amplification and/or overexpression in gastric carcinoma. ErbB-2 expression has been reported at rates of 8% to 28% in various studies (4) (5) (6) (7) (8) (9) (10) (11) . ErbB-2 gene amplification in gastric carcinoma is associated with an intestinal-type histology and poor survival (12, 13) . A case report and cell line and xenograft model studies have shown that trastuzumab has a growth inhibitory effect in ErbB-2 amplified and/or overexpressed gastric carcinomas (2) . Positive results of a large-scale phase III trial on the efficacy of trastuzumab have been reported in patients with gastric carcinoma with ErbB-2 expression (14) . Therefore, the evaluation of ErbB-2 gene amplification status in patients with gastric carcinoma has become important in determining the eligibility for trastuzumab therapy.
ErbB-2 status in tumor samples can be determined using various methods. Immunohistochemistry (IHC), Western blotting, and enzyme-linked immunosorbent assay are currently used to measure HER-2 protein expression; and HER-2 gene amplification can be detected by Southern blotting, fluorescence in situ hybridization (FISH), chromogenic in situ hybridization, and real-time quantitative polymerase chain reaction (RT-PCR). In practice, IHC and FISH methods are more often used. IHC is faster and more economical, but is highly dependent on quality control and is difficult to standardize. FISH is regarded as the standard in evaluating the presence of ErbB-2 gene amplification. However, it is expensive in terms of equipment and is labor intensive. Furthermore, FISH is not valuable when tissue samples are not well fixed. To overcome these limitations, alternative methods such as real-time RT-PCR are used experimentally in patients withgastric carcinoma; and the reported results have shown relatively good concordance rates (2) .
In the present study, we aimed to investigate the frequency of ErbB-2 overexpression and its relationship to pathologic parameters in gastric cancer, which is commonly seen around Eastern Anatolia in Turkey.
MATERIAL and METHODS
This study was conducted according to the ethical principles of the Declaration of Helsinki. Approval for the study was obtained from the Atatürk University Medical School ethics committee. All patients provided written informed consent upon enrollment.
Thirty-two patients who were diagnosed with gastric cancer in the departments of General Surgery and Internal Medicine at Atatürk University Medical School were enrolled in our study. All patients were newly diagnosed and treatment-naive.
Primarily, pathology samples of patients with gastric cancer were investigated to determine appropriate paraffin blocks. For the isolation of DNA, paraffin blocks were used in samples containing more than 30% tumor content. According to the recommendations of our medical biology laboratory and the guidance of Dr. Zeydanli DNA Isolation Kit From Paraffin-embedded Tissue, paraffinized tumor tissues were cut into sections of 5-7 μm and deparaffinized. DNA extraction was performed on deparaffinized samples with the DNA isolation kit [Dr. Zeydanli DNA Isolation Kit from Paraffin-embedded Tissue, Turkey (DZDNA)]. Tumor histology, level of differentiation, depth of tumor invasion and lymph node status were determined. The presence of distant metastases, tumor, node, metastasis (TNM) stage and localization of the gastric cancer were obtained from patients' records.
Quantitative measurement of the ErbB-2 oncogene from DNA extracts of tumor tissues was performed by using Light Cyler 2.0 (LC). The RT-PCR device was provided by Roche Diagnostic systems. Before processing, LC RT-PCR device calibration was checked with the kit that includes Calibrator DNA as a positive and negative control template provided by Roche Diagnostic systems (Roche, Mannheim, Germany). LC HER2/neu DNA Quantification Kit was used for the quantitative measurement of the ErbB-2 oncogene. Results of samples analyzed by the LC RT-PCR program were transferred to "Quantification Software".
The ratio of targeted HER2/Neu gene copy number to the reference gene copy number was calculated for each sample. If the ratio was <2, HER2/Neu oncogene amplification was considered to be negative, whereas the ratio was ≥2, HER2/Neu oncogene amplification was defined as positive.
Statistical analysis
The data were expressed as number, percentage, mean and standard deviation, and data analysis was performed using a computer program. Analysis of categorical variables was performed by Chisquare test. A value of p <0.05 was regarded as statistically significant.
RESULTS

The patients' characteristics
Patient characteristics are shown in Table 1 . The mean age of the patients was found to be 58.4±12.38 (32-84) years. Seventeen patients (53.1%) were male and 15 patients (46.9%) female. The histopathologic diagnosis of 32 (100%) patients was adenocarcinoma.
Distant metastases was detected (liver, adrenal gland, periton, ovary, pancreas) in 11 (34.3%) patients.
The tumors were more localized in the cardia (40.6%) and antrum (34.3%), and were more poorly-differentiated (65.7%) and moderately-differentiated (28.1%). Regarding lymph node involvement: 8 patients (25%) were detected to be N0 (no lymph node metastases), 10 (31.3%) N2 (the number of metastatic lymph nodes is between 7-15) and 9 (28.1%) N3 (the number of metastatic lymph nodes is higher than 15).
The quantitative results of ErbB-2 oncogene and distribution measured by RT-PCR
The ratio of ErbB-2 oncogene measured by RT-PCR to the reference gene ranged between 0.21 and 15.6. The mean value was 2.03±3.01. ErbB-2 amplification was found to be positive in five (15.6%) of the cases and negative in 27 (84.4%). Table 2 shows the relationship between pathological characteristics of the patients and ErbB-2 amplification. The relationship between distant metastases and ErbB-2 positivity was found to be statistically significant (p=0.04). Distant metastases were present in four ErbB-2 positive patients, whereas no distant metastases were observed in one patient.
The relationship between ErbB-2 oncogene and prognostic factors
The relationship between ErbB-2 positivity and parameters such as the level of differentiation (p=0.7), the depth of tumor invasion (p=0.08), lymph node involvement (p=0.6), Lauren classification (p=0.4), World Health Organization (WHO) classification (p=0.3), TNM staging (p=0.3) and location of the tumor (p=0.2) were not found to be statistically significant. On the other hand, lymph node involvement was present in all ErbB-2 positive patients. The tumors were T3 (one case) and T4 (four cases) and the cardia was a more common location, though not statistically significant (p>0.05).
DISCUSSION
Since good clinical outcomes were achieved by anti HER2/Neu antibody in breast cancer, the investigation of HER2/Neu expression in other solid tumors has become a current issue. In numerous studies so far, ErbB-2 overexpression was detected in varying rates in some tumors (i.e; breast, colon, bladder, ovarian, endometrial, lung, uterine cervix, head-neck and gastrointestinal system tumors) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) .
ErbB-2 overexpression in gastric cancer was first demonstrated by IHC staining in 1986 (3). ErbB-2 overexpression in gastric cancers exhibits some similarities to those in breast cancer (26) . ErbB-2 expression has been reported at rates of 8% to 28% in various studies (4-11). ErbB-2 positivity was found to be 22.1% in the ToGA study with 3807 gastric cancer patients in which 130 centers from various countries participated (14) . In our study, ErbB-2 overexpression was found in 15.6% of 32 gastric cancer patients. The rate of ErbB-2 overexpression in our study is generally consistent with other studies.
The results of studies that investigate the relationship between ErbB-2 overexpression and prognostic factors (the depth of tumor invasion, lymph node metastases, histological type, distant metastases, serosal invasion, and growth pattern) vary ErbB-2 overexpression and gastric cancer widely. ErbB-2 overexpression was found to be statistically significantly higher in gastric cancers which exhibit one of the following features: Welldifferentiated, advanced stage, papillary-type, presence of liver metastases, serosal invasion or lymph node involvement (6, 26, 27) . Sausa et al. (7) demonstrated that there was an association between ErbB-2 overexpression and tumor location and venous invasion. Jain et al. (28) also reported that there was a relationship between ErbB-2 positivity and intestinal type, tubular type and expansive-spread pattern. However, some studies reported that no significant relationship was detected between ErbB-2 overexpression and the depth of tumor invasion, lymph node involvement, venous invasion, the localization of the tumor and concluded that ErbB-2 was not a good predictor for prognosis (5, 12, 29, 30) .
In the present study, the relationship between ErbB-2 positivity and distant metastases was found to be statistically significant (p=0.04). Distant metastases were present in four ErbB-2 positive patients, whereas no distant metastases were observed in one patient. The relationships between ErbB-2 positivity and depth of tumor invasion (p=0.08), lymph node involvement (p=0.6) and tumor location (p=0.2) were not found to be statistically significant in our study. Lymph node involvement was present in all ErbB-2 positive patients and the depths of tumors invasion were T3 (one case) and T4 (four cases), which were remarkable, though not statistically significant (p>0.05). The findings indicating that the tumor was localized to the cardia in three ErbB-2 positive patients, in the corpus/cardia in one patient and in the corpus/antrum in one case were also remarkable.
A vast majority of studies on gastric cancer patients have reported that ErbB-2 overexpression was more common in the intestinal-type according to Lauren's classification and in the tubular or tubulopapillary type according to WHO (6, 7, 10, 13 well-differentiated adenocarcinomas compared to poorly-differentiated adenocarcinomas (29, 31) . In a study on gastric cancer patients, Kimura et al. (12) found that there was a relationship between ErbB-2 overexpression and histological differentiation, and concluded that ErbB-2 overexpression was more common in patients with well-differentiated gastric adenocarcinomas. Allgayer et al. (32) reported that ErbB-2 overexpression was more common in patients with well-differentiated adenocarcinomas. However, the difference did not reach statistically significance.
In our study, ErbB-2 overexpression was observed to be more common in patients with poorly-differentiated adenocarcinoma. Of five cases in whom overexpression were detected, four were poorlydifferentiated and one was moderately differentiated. However, no statistical difference was detected between ErbB-2 overexpression and the level of histological differentiation (p>0.05). In our study, ErbB-2 overexpression was investigated by RT-PCR without performing IHC staining or FISH. The positive rate of ErbB-2 gene expression was 15.6% in the tumor tissue of our patients. The results were consistent with those performed with RT-PCR.
In conclusion, given the rate of ErbB-2 overexpression in gastric cancer, it is appropriate to investigate ErbB-2 overexpression in gastric cancer patients as administration of monoclonal antibody treatment (trastuzumab) would be effective in ErbB-2 positive cases. Since it is considered that such a treatment would be an eligible option for at least 15-20% of patients, trastuzumab is believed to bring a new perspective to current neoadjuvant chemotherapy. This treatment may also increase the success of the surgical treatment and provide a complete recovery for many patients.
